



**Test Report**

**Melissa Secco**  
64 Twiss Lane  
Hollis, NH 03049  
USA

Optigen Accession #: **07-10483**  
Report issued for: **Carbon**

**OptiGen Test Certificate**

**Optigen Accession #: 07-10483**

**Report Issued: 11/19/2007**

Test Performed: **prcd Mutation Test for PRA**

**Result: Normal**  
**Sample Type: Blood**

Registered Name: **Mirabelle Woodduck Carbon Copy**

**Reg#: SR32254002**

Breed: **Labrador Retriever**

**ID#: 474E735476**

Sex: **Male**

Date of Birth: **January 08, 2006**

Owner(s):

**Melissa Secco**

**Dana L Loud**

**Jeanne M Charest**



*Jeanette S Felix*  
OptiGen Authorized Signature

[www.optigen.com](http://www.optigen.com)

Test Results: Genotype of your dog is Normal/Clear.

Risk for developing prcd-PRA: This dog will never develop the prcd form of PRA (progressive rod-cone degeneration form of Progressive Retinal Atrophy). So far, the only inherited PRA disease known in dogs of your breed is the prcd form of PRA.

Significance for breeding: Genetically Normal/Clear dogs can be bred to any dog and will produce no pups affected with the prcd form of PRA.

For further information, please consult the OptiGen website at [www.optigen.com](http://www.optigen.com).

**International DNA Based Genetic Database:** To register this result with OFA, make a copy, sign below, mail WITH FEE, to OFA, 2300 E. Nifong Blvd, Columbia, MO 65201-3856 or FAX to 573-875-5073. [www.offa.org](http://www.offa.org)

I hereby certify that the sample submitted was of the animal described on this application. I authorize the OFA to release all information on the test results thus placing the results in the public domain and I hereby release OFA from any and all liability associated with the release of test information.

Signature of owner or authorized representative: \_\_\_\_\_

**Cornell Business & Technology Park**

tel: 607.257.0301

fax: 607.257.0353

767 Warren Road, Suite 300, Ithaca, NY 14850

email: [genetest@optigen.com](mailto:genetest@optigen.com)

web: [www.optigen.com](http://www.optigen.com)